Vigil Neuroscience to Present at Upcoming September Investor Conferences

Rhea-AI Summary

Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotech company focusing on microglia-based treatments for neurodegenerative diseases, has announced its participation in two upcoming investor conferences in September 2024:

1. Morgan Stanley 22nd Annual Global Healthcare Conference: A fireside chat scheduled for Thursday, September 5th at 2:35 p.m. ET.

2. H.C. Wainwright 26th Annual Global Investment Conference: Another fireside chat set for Tuesday, September 10th at 10:30 a.m. ET.

Both events will feature live webcasts available on the company's website under the 'Events & Presentations' page in the 'Investors' section. These webcasts will remain accessible for approximately 90 days after the presentations.

WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of management will present at two upcoming investor conferences.

Morgan Stanley 22nd Annual Global Healthcare Conference
Format: Fireside Chat
Date/Time: Thursday, September 5th at 2:35 p.m. ET

H.C. Wainwright 26th Annual Global Investment Conference
Format: Fireside Chat
Date/Time: Tuesday, September 10th at 10:30 a.m. ET

The live webcasts from the events will be available on the Company’s website on the “Events & Presentations” page in the “Investors” section. Archived webcasts will be available for approximately 90 days following the presentation.

About Vigil Neuroscience

Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Iluzanebart, Vigil’s lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) patients, including some who carry TREM2 and other disease-associated variants.

Internet Posting of Information

Vigil Neuroscience routinely posts information that may be important to investors in the “Investors” section of its website at https://www.vigilneuro.com. The company encourages investors and potential investors to consult our website regularly for important information about Vigil Neuroscience.

Investor Contact:
Leah Gibson
Vice President, Investor Relations & Corporate Communications
Vigil Neuroscience, Inc.
lgibson@vigilneuro.com

Media Contact:
Megan McGrath
CTD Comms, LLC
megan@ctdcomms.com

FAQ

When is Vigil Neuroscience (VIGL) presenting at the Morgan Stanley Global Healthcare Conference in September 2024?

Vigil Neuroscience (VIGL) is scheduled to present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5th, 2024, at 2:35 p.m. ET.

What type of presentation will Vigil Neuroscience (VIGL) give at the H.C. Wainwright Global Investment Conference in September 2024?

Vigil Neuroscience (VIGL) will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10th, 2024, at 10:30 a.m. ET.

How can investors access Vigil Neuroscience's (VIGL) presentations at the September 2024 conferences?

Investors can access live webcasts of Vigil Neuroscience's (VIGL) presentations on the company's website under the 'Events & Presentations' page in the 'Investors' section. Archived webcasts will be available for about 90 days after the presentations.

What is the focus of Vigil Neuroscience's (VIGL) research and development?

Vigil Neuroscience (VIGL) is a clinical-stage biotechnology company focused on harnessing the power of microglia for the treatment of neurodegenerative diseases.